Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab Safety in Japanese Patients with Severe Asthma
NCT04048343Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in severe asthma, sponsored by AstraZeneca. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT04048343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048343.